Skip to main content
. 2021 Jul 30;13(8):1508. doi: 10.3390/v13081508

Figure 2.

Figure 2

ACE2-RBD-inhibiting antibody, SARS-CoV-2 specific IgG and microneutralization test results of 119 convalescent samples, 86 vaccinated samples and 299 health control samples. (A) ACE2-RBD-inhibiting antibody concentration. (B) ACE2-RBD binding inhibtion. (C) S1-IgG. (D) RBD-IgG. (E) N-IgG concentrations. (F) Neutralizing antibody titer of 119 convalescent samples, 86 vaccinated samples, and 299 health control samples were measured using CLIA and MNT. The 119 convalescent samples results are shown as red dots, the 86 vaccinated samples results are shown as blue dots, and the 299 health control samples results are shown as black dots. Dashed lines represent the cutoff for positive sample designation, determined by ROC curve. Results between each paired groups were analysis by t test, and means significant differences between two groups were shown as ** (p < 0.01) and * (p < 0.05). No significant difference was shown as ns, p > 0.05.